

Title: Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma With Uncommon

Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A

Multicenter Observational Study

Ping-Chih Hsu^{1,2}, Suey-Haur Lee³, Li-Chung Chiu^{1,2}, Chung-Shu Lee^{1,4}, Chiao-En Wu^{2,5}, Scott Chih-Hsi Kuo^{1,2}, Jia-Shiuan Ju¹, Allen Chung-Cheng Huang¹, Shih-Hong Li¹, Ho-Wen Ko^{1,2}, Cheng-Ta Yang^{1,6,7}, Chin-Chou Wang^{2,4*}

1. Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City 33305, Taiwan
2. Department of Medicine, College of Medicine, Chang Gung University, Taoyuan City 33302, Taiwan
3. Division of Pulmonary & Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City 83301 Taiwan.
4. Department of Thoracic Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City 23652, Taiwan
5. Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City 33305, Taiwan
6. Department of Internal Medicine, Taoyuan Chang Gung Memorial Hospital, Taoyuan City 33378 Taiwan.
7. Department of Respiratory Therapy, College of Medicine, Chang Gung University, Taoyuan City 33302 Taiwan

Supplementary Table S1. Subsequent treatment in patients experiencing progressive disease after 1st-line afatinib therapy

	With G719X	Without G719X	P Value
Progressive disease to 1st-line afatinib	Total n =34 (%)	Total n =35 (%)	
EGFR-T790 M mutation tests	13 (38.2%)	16 (45.7%)	0.628
Tissue rebiopsy	11 (32.4%)	15 (42.9%)	
Circulating tumor(ct)-DNA	2 (5.8%)	1 (2.8%)	
EGFR-T790 M mutation			1.000
Positive	4 (30.8%)	4 (25%)	
Negative	9 (69.2%)	12 (75%)	
Unknown (No rebiopsy and ctDNA)	21(61.8%)	19 (54.3%)	
Systemic therapy following 1st-line afatinib			
Osimertinib	4 (11.8%)	5 (14.3%)	1.000
Other 3rd-generation EGFR-TKI*	0	1 (2.8%)	0.321
1st-generation EGFR-TKI	2 (5.8%)	3 (8.6%)	1.000
Chemotherapy	16 (47.1%)	9 (25.7%)	0.0824
Platinum-based doublet	14 (41.2%)	6 (17.1%)	0.0356
Single agent chemotherapy	2 (5.8%)	3 (8.6%)	0.667
Anti-angiogenesis agents (Bevacizumab or ramucirumab)	1 (2.9%)	1 (2.8%)	0.983
Supportive care (no systemic treatment)	12 (35.3%)	17 (48.6%)	0.332

EGFR-TKIs: epidermal growth factor receptor-tyrosine kinase inhibitors.

*Almonertinib (HS-10296)